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The amyloid-𝛽 peptide or A𝛽 is the key player in the amyloid-cascade hypothesis of Alzheimer’s disease. A𝛽 appears to trigger
cell death but also production of double-strand breaks (DSBs) in aging and Alzheimer’s disease. All-trans retinoic acid (RA), a
derivative of vitamin A, was already known for its neuroprotective effects against the amyloid cascade. It diminishes, for instance,
the production ofA𝛽 peptides and their oligomerisation. In the presentworkwe investigated the possible implication of RA receptor
(RAR) in repair of A𝛽-induced DSBs. We demonstrated that RA, as well as RAR agonist Am80, but not AGN 193109 antagonist,
repair A𝛽-induced DSBs in SH-SY5Y cells and an astrocytic cell line as well as in the murine cortical tissue of young and aged
mice. The nonhomologous end joining pathway and the Ataxia Telangiectasia Mutated kinase were shown to be involved in RA-
mediated DSBs repair in the SH-SY5Y cells. Our data suggest that RA, besides increasing cell viability in the cortex of young and
even of aged mice, might also result in targeted DNA repair of genes important for cell or synaptic maintenance.This phenomenon
would remain functional up to a point when A𝛽 increase and RA decrease probably lead to a pathological state.
1. Introduction
DNA damage, such as DNA single- or double-strand breaks
(DSBs), is known to occur in aging [1, 2] as well as in Alz-
heimer’s disease (AD) [2–6]. Recently DSBs were shown to be
produced by A𝛽 or amyloid-𝛽 peptides [7, 8] through oxida-
tive stress [9]. Furthermore, A𝛽 peptides not only increase
neuronal vulnerability (e.g., apoptosis) in DNA-depend-
ent Protein Kinase (DNA-PK) deficientmice, a key enzyme of
the Nonhomologous End Joining (NHEJ) pathway involved
in DSBs repair [10], but also reduce the activity of this
enzyme [11, 12]. Thus, extracellular A𝛽 peptides trigger DSBs
production and impair DSBs repair.
However, if numerous factors are contributing to the for-
mation or increased levels of A𝛽 peptide, such as mainly age,
the apoE4 allele, cholesterol rich food, or glucocorticoid stress
hormone dexamethasone, others factors, such as the apoE2
allele and the growth factor BDNF, are neuroprotective [13,
14] or participate in “adaptive cellular responses” [15]. Among
them, some even diminishes DNA damage.This is the case of
glutamine that reduces etoposide-induced damage [16] and
of NAD that attenuates A𝛽-induced DNA damage [8].
In this study we were particularly interested in all-trans
retinoic acid (RA) [17–20], a derivative of vitamin A [21].
RA is known to be involved in development, neuronal differ-
entiation [22], spine formation through the RAR𝛼 receptor
[23], cell growth arrest in anticancer therapy [24], and mem-
ory decline in aging [25–27]. The neuroprotective role of
vitamin A and RA in relation to AD and to the 𝛽-amyloid
cascade—not to DNA DSBs—has intensively been studied,
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for example, [28]. Firstly, RA was shown to increase, via
its RAR𝛼 receptor, the expression of the major 𝛼-secretase,
ADAM10 (A Disintegrin and Metalloproteinase domain-
containing protein 10), diminishing the production of A𝛽
peptides [29]. This effect is mediated by RA-responsive
elements upstream of the ADAM10 coding region [30, 31].
RA can also inhibit the 𝛾-secretase activity through activation
of the Extracellular Signal Regulated Kinase, ERK1/2 [32].
Secondly, vitamin A and its derivatives appear to inhibit A𝛽
oligomerisation in vitro, A𝛽 deposition, and tau phosphory-
lation in AD mouse models [33]. Thirdly, RAR𝛼 signaling
removes A𝛽 plaques and induces A𝛽 oligomers clearance
via Neprilysin and Insulin Degrading Enzyme [34]. On the
contrary, A𝛽 is increased in the cerebral vasculature while
RAR𝛼 is decreased in the neocortex of rats maintained on
a 1-year retinoid-deficient diet [35]. Finally, following a RA
treatment in APP/PS1 double-transgenic mice, A𝛽 deposits,
AICDs (the Amyloid precursor protein Internal C-terminal
Domains), tau phosphorylation, and glial response were
decreased, whereas spatial learning was improved [36].
RAR are major players in the neuroprotective effects of
RA.RAbybinding to themallows the formation ofRAR/RXR
heterodimers and the replacement of corepressors, such as
HDAC (histone deacetylase), by coactivators, such as CBP
(CREB-binding protein). The histone acetyltransferase activ-
ity of CBP [37] and the down-regulation of DNA methyl-
transferases [24] result in RA-dependent transcription.
Indeed, RA hypomethylates promoters, such as the one of
RAR𝛽2 or of methyltransferases, altering gene transcription
[24].
According to these data, we wondered if, as a conse-
quence of local chromosome relaxation, DNA repair proteins
[2], such as the catalytic subunit of DNA-PK and Ataxia
Telangiectasia Mutated kinase (ATM), could be recruited at
chromosome sites of RA-dependent gene expression and if
DSBs could be repaired at these sites. We have investigated
whether RA and its receptor (RAR) might be involved, not in
prevention of A𝛽 synthesis, A𝛽 oligomerisation, and plaques
removal, as already shown, but in repair of A𝛽-inducedDSBs.
We showed—to our knowledge for the first time—that this
is indeed the case by studying neuronal and astrocytic cell
lines as well as neocortical tissue from young and old mice.
Furthermore, we examined the repair mechanisms involved
and the consequences on cell viability, in the search for effect-
ive early AD therapies.
2. Materials and Methods
2.1. Mice, Tissue Samples, and Dissections. C57BL/6J male
mice (Janvier, Le Genest-St-Isle, France) were sacrificed at
4 months (young adults) and at 16 months (aged adults).
Brains were quickly removed and cortices dissected under
a binocular microscope, weighted, and homogenized (about
5 sec with a Polytron apparatus, VWR International) in neu-
robasal medium (Gibco Life Technologies). The homoge-
nized tissue was immediately treated as described below.
Animals were handled in accordance with Federal Swiss
Veterinary regulations and approval.
2.2. Culture of Neuronal SH-SY5Y Cells and of Astrocytic DI
TNC1 Cells. Human SH-SY5Y cells (European Collection of
Animal Cell Culture, UK) were routinely grown in a 37∘C
incubator containing 5% CO
2
/95% humidified air in RPMI-
1640 (Gibco Life Technologies) with 10% FCS (Bioconcept,
Switzerland), 2mM L-glutamine (Gibco Life Technologies),
100 IU/mL penicillin G, and 100 𝜇g/mL streptomycin (Invit-
rogen). Cells were halved every 5 to 6 days. For this purpose,
the confluent cells were released in DPBS (150mM NaCl,
3mM KCl, 1.5mM KH
2
PO
4
, 7.9mM Na
2
HPO
4
⋅2H
2
O, and
0.1mMEDTA; pH7.4), centrifuged at 1000 rpmduring 5min,
and resuspended in RPMI-1640 and 10% FCS at the desired
dilution.
The DI TNC
1
cell line [38, 39] was grown in DMEM
medium (Sigma) supplemented with 10% FCS in a 37∘C incu-
bator containing 5%CO
2
/95% humidified air. Confluent cells
were released in trypsin solution (0.25%), centrifuged at
1100 rpm during 5min, and resuspended in DMEMwith 10%
FCS at the desired dilution.
Cells were photographed with an inverted phase contrast
microscope (ZEISS Telaval 31) using a photo camera (Leica
DFC 490) with the FireCam analyst software (Leica).
2.3. Tissue and Cell Treatments. For the cell treatments, two
days before experiment, the medium with 10% FCS was
replaced by the medium with 1% FCS. The cultured cells
and the homogenized cortical tissue (see before) were treated
or not with 20𝜇M monomeric A𝛽
1–42 peptides (Enzo Life
Sciences), during the first 30min, then with or without
5 𝜇M RA (Sigma-Aldrich) for 30 more min, resulting in four
combinations of 2 × 30min treatments (Ø-Ø; A𝛽
1–42-Ø; Ø-
RA; A𝛽
1–42-RA). Other treatments were carried out with
20𝜇M A𝛽
42–1, 20𝜇M A𝛽1–40 (Enzo Life Sciences), 10 𝜇M
RAR𝛼/𝛽 agonist Am80 (Santa Cruz Biotechnology), 1–
50 𝜇M RAR𝛼/𝛽/𝛾 antagonist AGN 193109 (Labforce), 50𝜇M
caspase-3 inhibitor z-VAD-FMK (Santa Cruz Biotechnology)
[40], 3 𝜇MHDAC inhibitor trichostatin A (TSA; Sigma) [41],
10 𝜇M inhibitor of Ataxia Telangiectasia Mutated kinase or
ATMKU55933 (KU; Labforce), and 150𝜇Minhibitor II of the
catalytic subunit of DNA-PK NU 7026 (NU; Calbiochem), in
combination with RA and/or A𝛽
1–42 for 30min or 24 h. All
treatments were carried out in triplicate in a 37∘C incubator
containing 5% CO
2
and 95% humidified air.
2.4. Neutral Single-Cell Gel Electrophoresis (Comet Assay).
DSBs were measured in SH-SY5Y cells, in DI TNC
1
cells,
and in the homogenized cortical tissue using Trevigen Comet
AssayTM kit (AMS Biotechnology, UK) with the following
modifications. After treatment, cells were resuspended in ice-
cold Ca2+ andMg2+ free PBS to a concentration of 1.0 to 1.5 ×
105 cells/mL. The same number of cells from the dissociated
cortical tissue was resuspended in the same solution with
the addition of 20mM EDTA and processed as for the cell
cultures. An aliquot of 50 𝜇L cells was added to 500𝜇L of
1% molten low-melting agarose (Seaplaque, FMC BioProd-
uct, USA) kept at 42∘C. Fifty microliters was immediately
spread on a comet slide (AMS Biotechnology), which was
incubated at 4∘C in the dark for 10min to accelerate agarose
gelling and then transferred to prechilled lysis solution (AMS
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Biotechnology) for 60min at 4∘C. Subsequently, the slide was
incubated in Neutral Electrophoresis Buffer (500mM Tris
base, 1.5M sodium acetate, pH 9.0) for 30min at 4∘C. DSBs
were separated by electrophoresis at 26V for 45min. Then,
the slideswere immersed in 70%ethanol at room temperature
for 30min and air-dried. DNA was stained 10min at room
temperature with 100𝜇L SYBR Green I dye (Gibco Life
Technologies) diluted 1 : 1000 in water and then rinsed with
distilled water. Comets of at least 30 cells per treatments were
immediately photographed using an Olympus digital camera
attached to an Olympus BX51 epifluorescence microscope
(Axio vision rel. 4.6).
2.5. Analysis of DSBs on Agarose Gel Electrophoresis. To vis-
ualize the average tail length of a treated cell population, 10𝜇L
of SH-SY5Y cells (1 × 105 cells/mL) was mixed with 5𝜇L lysis
buffer (AMS Biotechnology) for 5min at 4∘C and then 1.5 𝜇L
Tris EDTA 10x was added. The whole sample was loaded
into a slot of 1% agarose MP gel (Roche Life Science). A 1 kb
ladder (Invitrogen) was used as a sizemarker. Electrophoresis
was run for 40min at 66mV. The agarose gel was stained
by ethidium bromide (10mg/mL) and analyzed with a GS-
700 imaging densitometer (Bio-Rad). Signal intensities were
measured with the molecular analyst software program (Bio-
Rad).
2.6. Immunocytochemistry. Cortices of 4- (𝑛 = 3) and 16-
month-old C57BL/6J male mice (𝑛 = 3) were mechanically
dissociated and fixed for 30min at room temperature in
4% paraformaldehyde in PBS on coverslips pretreated with
100% alcohol. After rinsing for 3 × 5min with PBS, cells
were incubated for 1 h30 with the primary antibody diluted
in PBS. The mouse monoclonal anti-bIII-tubulin antibody
(Sigma), diluted 1 : 1000 in PBS, and the mouse monoclonal
anti-glial fibrillary acidic protein antibody (GFAP, Sigma),
diluted 1 : 500, were used. After rinsing for 5min with PBS,
coverslips were incubated for 1 h at room temperature with
the secondary anti-mouse IgG antibody coupled to Alexa-
Fluor 488 (Molecular probes/Invitrogen), diluted 1 : 1000, in
presence of Dapi (1.0 𝜇g/mL, Sigma) and rinsed for 3 ×
5min with PBS, and then mounted on glass slides fixed with
Fluorsave (Calbiochem).
Nine to twelve pictures of immunostained cells, corre-
sponding to 34 to 69 cells, were taken for each mouse using
a Zeiss Axioskop 2 plus microscope (Carl Zeiss, Feldbach,
Switzerland) equipped with epifluorescence and were digital-
ized with an Axiocam camera.
2.7. Cell Viability Assay. For assessing cell viability of SH-
SY5Y cells and DI TNC
1
cells, 20000 cells/well were grown
in 1mL RPMI-1640 with 10% FCS for 6–8 days and, two
days before the experiment, the medium was replaced by
RPMI-1640 with 1% FCS. For the cortical tissue, 1mg
freshly homogenized tissue was resuspended in 1mL of
the same medium. The cells were treated or not during
30min with 5𝜇M RA and/or 20𝜇M A𝛽
1–42 monomers or
3.3 𝜇L digitonin (CellTiter-Glo Luminescent Cell Viability
Assay, Promega) used as a positive control to decrease cell
viability. 100 𝜇L of cell suspension was shaken for 2min
with 100 𝜇L of CellTiter-Glo Reagent prepared according to
the manufacturer (CellTiter-Glo Luminescent Cell Viability
Assay, Promega) to induce cell lysis and to release the cell
ATP content, as indicator of metabolic activity. After 10min
incubation at room temperature, luminescence (in relative
light units) was recordedwith a luminometer (GloMax 20/20,
Promega).Mediumwithout cells or tissue samples resulted in
background luminescence.
2.8. Caspase-Glo. For assessing caspase-3 and caspase-7 acti-
vation, SH-SY5Y cells were grown in 1mL RPMI-1640 with
10% FCS. Two days before the experiment, the medium was
replaced by RPMI-1640 with 1% FCS. Cells were treated or
not during 30min or 24 h with 20𝜇M A𝛽
1–42, 50 𝜇M z-
VAD (in DMSO, Merk), or 100 nM staurosporine (Sigma-
Aldrich). 100 𝜇L of cell suspension was mixed for 2min with
100 𝜇L of Caspase-Glo 3/7 Reagent prepared according to the
manufacturer (Caspase-Glo 3/7 Assay, Promega) to induce
cell lysis and cleavage of a luminogenic substrate of caspase-
3/caspase-7. After 1 h30 incubation at room temperature,
luminescence was recorded with a luminometer (GloMax
20/20, Promega). A control without cells was also used.
2.9. Statistical Analysis. For the comet assay, values of mean
comet tail length were compared for each condition by a one-
way analysis of variance (ANOVA) to establish the effects of
various treatments. When overall statistically significant dif-
ferences in treatments effect were obtained by ANOVA, com-
parisons of means among subgroups were made after Bon-
ferroni corrections. In parallel, the nonparametric Kruskal-
Wallis test was used to compare the shape of comet tail
distribution also with Bonferroni corrections to compare
subgroups. The Kruskal-Wallis analysis is particularly suit-
able when the number of measures is small (less than 15 per
group) or when the distribution is not Gaussian (asymmetric
box plot). Level of significance is 𝑃 < 0.05. Analyses were
carried out with the Stata 13.1 software (Stat Corp., TX, USA,
2013).
3. Results
3.1. Retinoic Acid Repairs A𝛽-Induced DSBs in SH-SY5Y
and DI TNC1 Cells. To demonstrate that RA can repair
A𝛽-induced DSBs, SH-SY5H cells and astrocytic DI TNC
1
cells were treated with A𝛽
1–42 for half an hour before the
addition or not of RA for also 30min. The presence of
RA resulted in shorter tail lengths comparable to untreated
lysed cells (Figures 1(a) and 1(b)). The mean comet tail
length was significantly higher in A𝛽 treated SH-SY5Y cells
as well as DI TNC
1
cells compared to all other treatments
(Figures 1(c) and 1(d)). These results were corroborated by
an independent experiment showing on an agarose gel comet
tails starting from their cell nuclei loaded into the gel’s slots.
Short DNA fragments—between about 0.85 kb and 3.0 kb—
were generated more frequently when A𝛽 was present and
were reduced in number in presence of RA (Figure 1(e)).
Apoptotic fragments of 𝑛 × 180 bp could not be detected,
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Figure 1: RA repairs A𝛽-induced DSBs in SH-SY5Y and astrocytic DI TNC
1
cells. (a) Representative pictures of comets with various tail
lengths of SH-SY5Y cells or of (b) DI TNC
1
cells following 30min RA (5𝜇M) and/or 30min A𝛽 (20𝜇M) treatments. Ø = without treatment
for 30min; scale bar: 200 𝜇m. (c) Box plots of mean comet tail lengths of SH-SY5Y cells (number of cells measured: 31 < 𝑛 < 53) and of (d)
DI TNC
1
cells (31 < 𝑛 < 36). ANOVA with Bonferroni correction: ∗𝑃 < 0.05; ns = not significant. (e) Agarose gel electrophoresis showing
comet tails of about 1 × 103 lysed SH-SY5Y cells per well treated with RA (5𝜇M) and/or A𝛽 (20 𝜇M). Each treatment was carried out twice. A
1 kb ladder (Invitrogen) was used. (f) Graphical representation of mean optical DNA intensities for each duplicated treatment in (e). It shows
that RA decreases the amount of A𝛽-induced DSBs and corroborates Fig. (c). The DNA intensities were measured for 1 kb to about 20 kb
DNA.
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Figure 2: Control experiments for the effects of A𝛽 and RA on mean comet tail lengths in SH-SY5Y cells. (a) Box plot of mean comet tail
lengths according to 30min treatments withA𝛽
1–42 and control peptidesA𝛽42–1 orA𝛽1–40 (20𝜇MA𝛽; number of cellsmeasured: 33 < 𝑛 < 48).
(b) Box plot of mean comet tail lengths depending on 30min treatments of various RA concentrations (25 < 𝑛 < 35). (c) Box plot of mean
comet tail lengths according to 30min treatments with 20𝜇MA𝛽
1–42, 5𝜇MRA, 10 𝜇MRAR𝛼/𝛽 agonist Am80, and its solventDMSO (1% v/v),
demonstrating a similar specific effect of RA and of Am80 in SH-SY5Y cells (26 < 𝑛 < 41). (d) Box plot of mean comet tail lengths according
to the RAR𝛼/𝛽/𝛾 antagonist AGN 193109 (1–50𝜇M AGN) in presence or absence of 5 𝜇M RA (28 < 𝑛 < 49). The reduced mean tail length
due to RA is abolished in presence of AGN. ANOVA with Bonferroni correction: ∗𝑃 < 0.05; ns = not significant; Ø = without treatment for
30min.
suggesting that apoptosis was not activated under these
30min treatments. Quantification of signals intensities up to
the gel’s slots revealed that DSBswere almost halvedwhenRA
was added after A𝛽 (Figure 1(f)).
3.2. Retinoic Acid Repairs A𝛽1–42-Induced DSBs in a Concen-
tration-Dependent Manner via RAR𝛼/𝛽 in SH-SY5Y Cells.
We demonstrated that DSBs are induced specifically by
the A𝛽
1–42 peptide and not by the nonpathological A𝛽1–40
form or a control peptide with the reverse sequence A𝛽
42–1,
all treatments being carried out for 30min with 20𝜇M
A𝛽 peptides (Figure 2(a)). A similar result was obtained
with DI TNC
1
cells. Furthermore, a dose-response curve
(Figure 2(b)) showed that RA repairs DSBsmost efficiently at
concentrations between 1𝜇Mand 50 𝜇M,with a peak ofmax-
imal efficiency at 5 𝜇M, whereas it had no effect at 0.5 𝜇M or
500𝜇M. Using a cell viability assay, we observed that a treat-
ment with 0.5 𝜇M RA (101.3 ± 15.3%) and 1 𝜇M RA (103.8 ±
8.6) resulted in a similar viability compared to that of the
untreated cells (100± 10%).However, the viability increased at
5 𝜇MRA (135.8 ± 30.8%), 10 𝜇MRA (152 ± 12.7%), and 50𝜇M
RA (126± 30.2) but dropped at 500𝜇MRA (27.1± 2.1) (𝑛 = 3).
Furthermore, we demonstrated in SH-SY5Y cells that the
RAR𝛼/𝛽 agonist Am80 used at a concentration of 10𝜇M had
the same effect compared to RA (Figure 2(c)). Both signifi-
cantly reduced A𝛽-induced DSBs. Moreover, no significant
difference was observed between Am80 and RA suggesting
that in SH-SY5Y cells the RAR𝛼/𝛽 receptor was sufficient to
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mediate all DSBs repair activity, thus excluding the involve-
ment of other potential receptors, such as PPAR𝛽/𝛿 [42].
Finally, the addition of 1 𝜇M RAR𝛼/𝛽/𝛾 antagonist AGN
193109 to 5𝜇M RA significantly impaired the diminution of
DSBs due to the RA treatment.This effect was even increased
with a higher concentration of AGN (50𝜇M compared to
1 𝜇M), clearly demonstrating that the binding of RA to its
RAR is needed to repair DSBs (Figure 2(d)).
3.3. Retinoic Acid Repairs A𝛽-Induced DSBs in the Neocortex
of Young and Aged C57BL/6J Mice. RA added half an hour
after the A𝛽
1–42 treatment can also repair DSBs in cells orig-
inating from the murine cortex of young (𝑛 = 3) and aged
C57BL/6J mice (𝑛 = 3). The presence of RA resulted in
shorter tail lengths comparable to untreated lysed cells and
cells treated with RA alone (Figures 3(a) and 3(b)). The
mean comet tail length was significantly higher in A𝛽 treated
cortical cells compared to all other conditions in the young
as well as in the aged mice (Figures 3(c) and 3(d)). However,
the difference in mean comet tail lengths between the A𝛽
treatment and the other conditions was less important in the
aged compared to the youngmice possibly due to a decreased
metabolism. Indeed, the difference between the A𝛽 and the
A𝛽 + RA treatment was statistically different in all 3 young
mice, but only in 2 aged mice out of 3. We further showed by
immunocytochemistry (Figure 3(e)) that the cells analyzed
in the comet assay consist in neurons (68% for pooled age
groups) as well as astrocytes (26%) and that the ratio of
astrocytes/neurons (0.38) was similar to that reported in the
literature [43] (Figure 3(f)).
3.4. Histone Deacetylase Inhibitor Trichostatin A and/or Ret-
inoic Acid Induce DSBs Repair through DNA-PK and ATM in
SH-SY5Y Cells. To ascertain the mode of action of RA via
its receptor RAR, SH-SY5Y cells were treated with histone
deacetylase (HDAC) inhibitor trichostatin A (TSA). We
observed that TSA decreased mean tail length produced
by A𝛽 as efficiently as RA (Figure 4(a)). Moreover, DSBs
were significantly decreased in cells treated with TSA + RA
compared to RA treated cell, suggesting a possible synergetic
effect of both chemicals as they act at different sites of the
same receptor complex [37].
Moreover, the inhibition of the RA repair activity was
shown to be mediated both by ATM using ATM inhibitor
KU 55933 and byDNA-PK usingDNA-PK inhibitor NU 7026
(Figure 4(b)). The ATM inhibitor induced as many DSBs
as the DNA-PK inhibitor or the A𝛽 treatment. In presence
of RA, inhibition of both pathways, but not of only one,
produced a similar amount of DSBs as the A𝛽 treatment.
Thus, both ATM and DNA-PK protein kinases need to be
present, so that RA is able to repair DSBs in SH-SY5Y cells.
3.5. Effects of A𝛽 onApoptosis and of RA onCell Viability. SH-
SY5Y cells were treated with A𝛽 and/or caspase-3 inhibitor z-
VAD. Staurosporinewas used as positive control for apoptotic
cell death. Only this last compound resulted in cell death after
24 h, but not after 30min treatment (Figure 5(a)). However,
in these cells, caspase-3 was already active after 30min
as demonstrated by z-VAD treatment (Figure 5(b)). Stau-
rosporinewas activating caspase-3 and caspase-7 after 30min
and even more after 24 h compared to the untreated cells.
However, statistical significance was not reached comparing
control treatment to staurosporine treatment, even if a
tendency towards significance increased at 24 h (𝑃 = 0.08)
compared to 30min (𝑃 = 0.92). After 30min, caspases were
already activated but cell death was not observed, whereas
after 24 h cells were dead and caspases could not be activated
further. A comet assay carried out under the same conditions
(Figure 5(c)) revealed that the mean comet tail length was
not diminished by z-VAD in presence of A𝛽 after 30min
compared to the A𝛽 treatment. In this case, DSBs were not
due to activated caspase-3. After 24 h, the mean comet tail
length was significantly reduced by z-VAD in presence of A𝛽
suggesting the production of DSBs due to activated caspase-
3. Overall, A𝛽-induced DSBs appear not to be related to
proapoptotic events after 30min treatment.
Furthermore, cell viability was measured by quantifica-
tion of intracellular ATP in comparison to cells lysed by
digitonin. After 30min A𝛽 treatment in presence or not
of RA, DI TNC
1
cell viability was neither decreased nor
increased, whereas it was the case subsequent to the digitonin
treatment (Figure 5(d)). An identical observation was made
for SH-SY5H cells (not shown). Cells from 4-month-young
neocortical tissue showed after 1 h a much higher viability
than cells from 16-month-old tissue (Figure 5(e)), suggesting
a higher fragility of the latter tissue in the in vitro conditions.
Overall viability dropped after 30min A𝛽 treatment due
to decreased intracellular ATP in the young tissue (𝑃 =
0.001). However, this decrease was less significant when RA
was added to A𝛽 for both young and old cortical tissues
(𝑃 = 0.036). We observed an increase in viability of about
53% for the young tissue and of about 59% for the old
tissue, indicating that under the experimental conditions RA
enhances viability at a time when DSBs are being repaired.
4. Discussion
Our main observation is that RA is involved in A𝛽-induced
DSBs repair in neuronal and astrocytic cell lines as well as in
the cortical tissue, likely in cortical neurons as well as astro-
cytes, and in young and even in agedmice. Truly the addition
of RA after DSBs production by A𝛽
1–42 treatment can repair
DSBs. This was shown by two independent methods: comet
assay and gel electrophoresis with SH-SY5Y neuroblastoma
cells.Thus, according to these data, RA and its receptor (RAR)
are involved not only in the prevention of A𝛽 synthesis,
A𝛽 oligomerisation, and plaques removal, as already shown
[29, 32–34, 36], but also in the A𝛽-induced DSBs repair.
4.1. A𝛽1–42 Induces DSBs with a Pathological Potential. We
choose to grow SH-SY5Y and DI TNC
1
cells in presence
of FCS 1% instead of FCS 10%. In both cases, A𝛽 induced
significantly more DSBs, but in the former condition cells
weremore differentiated as in the cortical tissue. L-Glutamine
was also added as it is already known to protect against
DSBs formation [16] and only the effect of RA had to be
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Figure 3: RA repairs A𝛽-induced DSBs in the neocortex of C57BL/6J mice. (a) Representative pictures of comets with various tail lengths of
cortical cells originating from young (4 months; 𝑛 = 3mice) or (b) aged (16 months; 𝑛 = 3) mice following 30min RA (5𝜇M) and/or 30min
A𝛽 (20𝜇M) in vitro treatments. Ø = without treatment for 30min; scale bar: 200 𝜇m. (c) Box plots of mean comet tail lengths of 3 young
(number of cells measured: 31 < 𝑛 < 56) and of (d) 3 aged mice (30 < 𝑛 < 51). Statistical analyses (ANOVA with Bonferroni correction)
revealed significant differences in all 3 youngmice (∗𝑃 < 0.05), whereas only 2 out of 3 (+𝑃 < 0.05) or 1 out of 3 agedmice (◊𝑃 < 0.05) reached
statistical significance; ns = not significant. (e) Immunofluorescent pictures of cortical cells of young mice stained with anti-𝛽III-tubulin to
mark neurons, anti-GFAP to label astrocytes, and DAPI as a nuclear marker. A similar study war carried out with cortical cells of aged mice.
(f) Proportions of neurons, astrocytes, and other cell types in the cortex of young (𝑛 = 3) and of aged mice (𝑛 = 3). Number of cells analyzed
for each mouse: 33 < 𝑛 < 70. 𝑃 < 0.05: comparison between neurons and astrocytes.
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Figure 4: Repair pathways of A𝛽-induced DSBs. (a) Box plot of mean comet tail lengths of SH-SY5Y cells (number of cells measured:
31 < 𝑛 < 47) after 30min treatments with RA (5𝜇M), the HDAC inhibitor TSA (3 𝜇M), and A𝛽 (20𝜇M) demonstrating the involvement of
HDAC. (b) Box plot of mean comet tail lengths of SH-SY5Y cells (20 < 𝑛 < 42) after 30min treatments with RA (5 𝜇M), A𝛽 (20𝜇M), KU
55933 (ATM inhibitor, 10𝜇M), and NU 7026 (DNA-PK inhibitor, 150 𝜇M) demonstrating the involvement of ATM and of DNA-PK. ANOVA
with Bonferroni correction: ∗𝑃 < 0.05; ns = not significant; Ø = without treatment for 30min.
tested. L-Glutamine was equally added to the homogenized
cortical tissue but B27 supplement was avoided as it contains
RA. Interesting was the observation that only the most
pathological form of A𝛽, A𝛽
1–42, was inducing DSBs in both
of the SH-SY5Y and DI TNC
1
cells, suggesting that A𝛽
1–42-
induced DSBs might play a role in Alzheimer’s pathology.
Noteworthy is also the fact that A𝛽
1–42 treatment appeared
to be less efficient in inducing DSBs in the aged than in the
young murine cortical tissue. This cannot be due to the state
of the A𝛽 that corresponds to a mixture of monomer and
oligomers in both cases [44] but rather to the state of the
tissue, such as a lower metabolism of the aged cortical tissue.
4.2. RA Has a Counteracting Effect on DSBs Production.
RA has been shown to reduce DSBs in a concentration-
dependent manner in SH-SY5Y cells. 5𝜇M RA appears to
be optimal for decreasing DSBs and increasing cell viability,
that is, ATP concentration, compared to the untreated cells.
Higher or lower RA concentrations resulted in unchanged
DSBs levels compared to the control cells, whereas increased
RA concentrations only decreased cell viability.This variation
of RA effect according to its concentration is compatible with
the observation that when neuronal activity is low, endoge-
nous RA synthesis is locally activated in order to maintain
the structures of neurons (homeostatic synaptic plasticity)
and that conversely RA synthesis decreases when neuronal
activity increases [20]. It has to be observed that the DSBs
levels following the RA treatments were not consistently
lower than the background DSBs levels of the untreated
samples. This phenomenon might be due to variations of
endogenous RA levels in relation to cell differentiation
or division. Furthermore, RA was shown to decrease A𝛽-
induced DSBs through the RAR𝛼/𝛽 receptors by using the
Am80 agonist and the AGN 193109 antagonist. The agonist
being as effective as RA in reducing DSBs, an effect of RA
through another receptor, for example, RXR-PPAR𝛽/𝛿 [42],
appears excluded in SH-SY5Y cells. The observation that
the HDAC inhibitor TSA, which enables derepression of
Retinoic Acid Response Element-dependent gene expression,
results in a similar decrease of A𝛽-induced mean comet
tail length as RA strengthens the role of RAR in repair of
A𝛽-induced DSBs. Reparation might occur either through
expression of genes involved in DSBs repair or more directly
through chromatin decondensation at sites of RA-dependent
gene expression allowing access to proteins involved in DSBs
repair. One of these proteins is DNA-PK of the NHEJ repair
pathway.However, its inhibitorNU7026, used at a concentra-
tion of 150𝜇M, resulted only in a partial repair of A𝛽-induced
DSBs compared to the RA treatment. A concentration effect
of NU was excluded as a dose-response curve demonstrated
that mean comet tails lengths reached a maximum size at 150
to 250𝜇M NU and decreased significantly at 50 to 100 𝜇M
NU (data not shown).TheATM inhibitor, KU 55933, resulted
equally in a partial repair of A𝛽-inducedDSBs.We showed in
SH-SY5Y cells that both of DNA-PK and ATM, known to be
complementary [45, 46], enable the complete counteracting
effect of RA on DSBs production.
4.3. Adaptive Cellular Response due to RA-Mediated DSBs
Repair: The DSB-PRAE Hypothesis. We observed that short-
term (not long-term) treatment with A𝛽 is not decreasing cell
viability or causing cell death and that caspase-3was activated
at the same level in presence of A𝛽 or not in SH-SY5Y grown
with 1% FCS. Indeed, even staurosporine is known to induce
neurite outgrowth in the short term before inducing cell
death and apoptotic DNA fragments in the long term [47].
We also did not observe apoptotic fragments of 𝑛 × 180 bp
after 30minA𝛽 treatment, suggesting that apoptosis is not yet
activated under these conditions. However, at that time, DSBs
are induced byA𝛽, and if not repaired in the longer term, they
might be deleterious [48]. Furthermore, in the short time,
RA can repair DSBs and appears even to increase viability in
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Figure 5: A𝛽 effects on the apoptotic cascade, onDSBs, and on cell viability in presence of the caspase-3 inhibitor z-VADor RA. (a) Pictures of
phase contrast microscopy with SH-SY5Y cells treated with 20𝜇MA𝛽 and/or 50 𝜇M z-VAD did not show cell death, whereas treatment with
100 nM staurosporine resulted in apoptotic cell death after 24 h, not after 30min. Scale bar = 200𝜇m. (b) Measures of caspase-3/caspase-7
(CaspaseGlo assay) after 30min and 24 h treatment with A𝛽 and/or z-VAD or staurosporine (STA). Caspases were activated in the control cell
cultures (Ø = without treatment) and in presence of A𝛽 after 30min and 24 h but were not able to induce cell death. A nonsignificant increase
of caspases between 30min and 24 h resulted in cell death (a). (c) Box plot of mean comet tail lengths after treatments with A𝛽 and/or z-VAD
shows that A𝛽-induced DSBs in SH-SY5Y are not related to apoptotic DSBs after 30min, whereas they are related to apoptotic DSBs at 24 h
(number of cells measured: 27 < 𝑛 < 38). (d) Measures of viability (Glomax assay) of astrocytic DI TNC
1
cells treated for 30min with RA
(5𝜇M) and/or A𝛽 (20 𝜇M) or digitonin (3.3mM) (𝑛 = 9). A similar result was observed with SH-SY5Y cells, that is, no alteration of viability
despite RA and/or A𝛽 treatments. (e) Measures of viability (Glomax assay) of cells from cortical tissue of young (dark gray; 4 months; 𝑛 = 3)
and aged mice (light gray; 16 months; 𝑛 = 3) after treatments with RA and/or A𝛽 or digitonin during 30min. Viability is less significantly
decreased in presence of RA. ANOVA with Bonferroni correction: ∗𝑃 < 0.05; ns = not significant; Ø = without treatment for 30min.
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the cortex of young and to a lesser extent of aged mice. The
fact that RA is repairing DSBs as Am80 and trichostatin A
and that both of them alter memorization [49, 50] suggests
a similar role for RA. We make the hypothesis that whereas
A𝛽 produces DSBs, RA results in targeted error-prone repair
of the subset of DNA regions with RA-dependent gene
expression, involved in particular in neuronal or synaptic
maintenance [23].This process of selective DNA repairmight
result in a neuronal state adapted to the metabolic changes
occurringwith aging.This phenomenonof “DSBs production
and repair-dependent adaptive gene expression” (DSB-PRAE
hypothesis) would remain functional up to a pathological
threshold reached by A𝛽 increase and RA decreased response
with aging and might be an explanation for the role of DSBs
in memorization [7].
In conclusion, we have found that RA repairs A𝛽-induced
DSBs in neural cells of the cerebral cortex. Our data are in
favor of a role of RA in increasing neural viability and also
possibly in providing a neuronal adaptive response. However,
this should be demonstrated notably in an ADmouse model.
Furthermore, our data suggest that a better knowledge of
themechanisms involved inA𝛽-inducedDSBsmight provide
additional means to target pathological A𝛽-induced changes,
not just by impairing the A𝛽-amyloid cascade but by repair-
ing some of its consequences.
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